.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01ED04_Brigatinib.Brigatinib .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01ED04_Brigatinib.Brigatinib| name: | Brigatinib |
| ATC code: | L01ED04 | route: | oral |
| n-compartments | 2 |
Brigatinib is a tyrosine kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). It is approved for use in patients whose disease has progressed on or who are intolerant to crizotinib.
Pharmacokinetic parameters were reported in adult patients with advanced malignancies including ALK-positive NSCLC, mostly aged 18-84 years, under steady-state following repeated dosing.
Gupta, N, et al., & Venkatakrishnan, K (2021). Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer. Clinical pharmacokinetics 60(2) 235–247. DOI:10.1007/s40262-020-00929-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32816246
Gupta, N, et al., & Sinha, V (2023). Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor. Clinical pharmacokinetics 62(8) 1063–1079. DOI:10.1007/s40262-023-01284-w PUBMED:https://pubmed.ncbi.nlm.nih.gov/37493887
Tugnait, M, et al., & Narasimhan, N (2019). The Effect of a High-Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers. Clinical pharmacology in drug development 8(6) 734–741. DOI:10.1002/cpdd.641 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30570839